uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Rhea-AI Summary
uniQure (Nasdaq: QURE) closed its upsized underwritten public offering of 5,686,813 ordinary shares at $45.50 per share, including full exercise of the underwriters’ option for 741,758 additional shares, raising approximately $259 million in gross proceeds.
Net proceeds will support AMT-130 commercialization readiness, a confirmatory study, other clinical programs, business development and general corporate purposes.
Positive
- Gross proceeds of approximately $259 million to strengthen liquidity
- Funding earmarked for AMT-130 commercialization readiness and confirmatory study
- Capital allocated to other clinical product candidates and research projects
- Supports business development initiatives alongside core R&D investment
Negative
- Issuance of 5,686,813 new shares implies equity dilution for existing holders
- Underwritten public offering at $45.50 per share may cap near-term share price
News Market Reaction – QURE
In the Jun 26 session, QURE declined 3.24%, reflecting a moderate negative market reaction. Argus tracked a trough of -9.4% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | Offering priced | Negative | -0.4% | Upsized underwritten public offering priced at $45.50 targeting about $225M gross. |
| Jun 22 | Proposed offering | Positive | +10.5% | Company launched proposed $150M underwritten offering with additional $22.5M option. |
| Sep 29 | Offering closed | Negative | -1.7% | Closed upsized offering raising ~$345M including full exercise of underwriters’ option. |
| Sep 25 | Offering priced | Positive | +3.1% | Priced upsized $300M public offering of ordinary shares and pre‑funded warrants. |
| Sep 24 | Proposed offering | Positive | +10.8% | Announced proposed $200M public offering of shares and pre‑funded warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent offering-related headlines have usually aligned with the immediate price reaction, often skewing positive on announcement and pricing days.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of
uniQure intends to use the net proceeds from this offering to fund its commercialization readiness activities, the potential commercial launches of AMT-130 and related commercialization activities, a confirmatory study for AMT-130, the development of its other clinical product candidates, business development initiatives and research projects, and for general corporate purposes.
Leerink Partners, Stifel, Guggenheim Securities and RBC Capital Markets acted as joint bookrunning managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.
The offering was made pursuant to uniQure’s automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A final prospectus supplement and the accompanying prospectus relating to the offering has been filed with the SEC and may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at +1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, New York 10281, by telephone at (877) 822-4089 or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the intended use of net proceeds from the public offering and other statements identified by words such as "estimate," "plan," "project," "forecast," "intend," "will," "shall," "expect," "anticipate," "believe," "seek," "target," "continue," "could," "may," "might," "possible," "potential," "predict" and similar words or expressions.
Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: continued interest in our rare disease and gene therapy portfolio, the ability to develop our product candidates and technologies, regulatory developments, the impact of changes in the financial markets and global economic conditions, and other factors described under the heading "Risk Factors" in uniQure’s periodic securities filings with the SEC, including our Annual Report on Form 10-K filed with the SEC on March 2, 2026, our Quarterly Report on Form 10-Q filed with the SEC on May 5, 2026, the final prospectus supplement and the accompanying prospectus filed with the SEC, and other filings that uniQure makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
| uniQure Contacts | |
| For Investors: | For Media: |
| Chiara Russo | Tom Malone |
| Direct: 781-491-4371 | Direct: 339-970-7758 |
| Mobile: 617-306-9137 | Mobile: 339-223-8541 |
| c.russo@uniQure.com | t.malone@uniQure.com |
